サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777586

胃がん治療の世界市場

Stomach Cancer Treatment

出版日
ページ情報
英文 371 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.67円
胃がん治療の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 371 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

胃がん治療の世界市場は2030年までに104億米ドルに達する

2024年に52億米ドルと推定される胃がん治療の世界市場は、2024～2030年の分析期間においてCAGR 12.1%で成長し、2030年には104億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標準化学療法は、CAGR 13.6%を記録し、分析期間終了時には70億米ドルに達すると予測されます。標的療法セグメントの成長率は、分析期間中CAGR 9.2％と推定されます。

米国市場は14億米ドルと推定、中国はCAGR16.6％で成長予測

米国の胃がん治療市場は、2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに22億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.7%と10.9%と予測されています。欧州では、ドイツがCAGR約9.7%で成長すると予測されています。

世界の胃がん治療市場- 主要動向と促進要因のまとめ

胃がん治療がヘルスケアシステム全体で世界的に再注目されている理由とは？

胃がんは、特に東アジア、東欧、ラテンアメリカの一部において、依然として世界のがん関連死亡の主要原因の1つです。食の安全性の向上、ヘリコバクター・ピロリの除菌、早期検診への取り組みなどにより、全体的な罹患率が低下している地域もあるが、多くの国では診断が遅く、治療へのアクセスが限られているため、依然として健康上の大きな課題となっています。世界のヘルスケアコミュニティは、胃がんに対する意識の高まり、検診イニシアチブの拡大、データ収集の改善により、胃がんの真の負担を強調することに焦点を移しつつあります。日本、韓国、中国などのリスクの高い国々では、組織的な検診プログラムにより、治癒可能な早期の段階でより多くの症例が発見され、根治的な外科的治療や薬理学的治療の需要が急増しています。胃がんがより進行した段階で発症する傾向がある欧米では、生存期間を延長し、QOLを改善する新規の全身療法に対する臨床的関心が高まっています。この新たな焦点は、世界規模で胃がんによる死亡率を管理し、最終的には減少させるために、製薬技術革新、医療システム計画、学術研究をより協調的で戦略的な取り組みへと押し上げています。

標的治療と免疫腫瘍学は治療の展望をどのように再定義しているのか？

胃がん治療の状況は、精密医療、バイオマーカー検査、免疫療法の進歩に後押しされ、大きな変革期を迎えています。従来、外科手術、化学療法、放射線療法で治療されてきた胃がんは、現在、分子サブタイプ、遺伝子変異、PD-L1発現レベルを考慮した、よりテーラーメイドのアプローチで管理されています。トラスツズマブなどのHER2標的療法は、HER2陽性胃がん患者の予後を著しく改善し、新しい抗体薬物複合体（ADC）やチロシンキナーゼ阻害剤は、他のがん原性因子に対する治療法を拡大しています。ペムブロリズマブやニボルマブのような免疫チェックポイント阻害剤は、進行性または転移性胃がん患者、特にマイクロサテライト不安定性（MSI-H）の高い患者や腫瘍変異負荷（TMB）の高い患者において有望な結果を示しています。免疫療法と化学療法や抗血管新生剤との併用療法は、抵抗性を克服し、奏効持続性を改善するために検討されています。リキッドバイオプシーと次世代シークエンシングは、より早くより正確な治療選択を容易にし、胃がん患者に対する個別化治療の時代の到来を告げています。規制当局の承認が加速し、臨床試験のパイプラインが充実するにつれて、これらの治療法の進歩は、一次治療と難治性治療の両方における標準治療を大幅に再編成すると予想されます。

市場需要はどこで拡大し、どのような患者集団が治療ニーズを牽引しているのか？

胃がん治療に対する市場需要は世界的に高まっているが、患者負担が最も大きいのは中国、日本、韓国などのアジア太平洋諸国で、世界の患者数の半分以上を占めています。これらの地域は、積極的なスクリーニング政策、強力な政府支援、確立された治療プロトコルが特徴で、早期介入と医薬品販売の両面でホットスポットとなっています。米国、ドイツ、英国を含む欧米諸国では、罹患率は比較的低いもの、胃がんの若年発症へのシフトと進行期発症率の高さが治療需要を高めています。ラテンアメリカ、東欧、アフリカの一部では有病率が増加しているが、発見の遅れ、治療インフラ、薬剤アクセスに関する課題に直面しており、ジェネリック化学療法剤、バイオシミラー、公衆衛生パートナーシップの機会が強調されています。新規診断の大部分を占める高齢患者は、より低毒性で忍容性の高いレジメンに対する需要を牽引しており、一方、若年患者は妊孕性温存治療や長期生存計画への関心を促しています。都市化、食生活の変化、発展途上地域におけるピロリ菌の持続的な感染も、治療対象人口の着実な拡大に寄与しており、タイムリーで効果的かつ安価な治療を提供する医療システムへの圧力を生み出しています。

世界の胃がん治療市場の長期的成長の原動力は？

胃がん治療市場の成長は、人口動向、進化する治療オプション、政策枠組み、診断の進歩の合流によってもたらされます。長期的な主要要因は世界人口の高齢化であり、胃がんのベースライン・リスクが増加し、治療を必要とする患者層が拡大しています。分子プロファイリングとコンパニオン診断の進歩により、腫瘍医は"画一的な"化学療法から、特定の腫瘍生物学を標的とする精密ベースのレジメンへと移行することが可能となり、有効性の向上と副作用の最小化が実現しつつあります。がん免疫療法の世界の拡大により、進行症例や以前は難治性であった症例に新たな治療の道が開かれつつあります。政府や医療機関は、早期発見と治療へのアクセスを優先するがん対策プログラムに投資しており、製薬会社は、特に併用療法や次世代生物製剤への研究開発投資の強化で対応しています。これと並行して、新興市場では腫瘍学のインフラ整備と医薬品償還政策の改革が進み、確立された治療法と新規治療法の両方へのアクセスが拡大しています。遠隔腫瘍学、電子カルテ、国際共同治験の役割の増大も、患者管理とデータに基づく治療の最適化を強化しています。胃がんに対する科学的理解が深まり、治療法の革新が進むにつれて、胃がん治療市場は、世界で最も侵攻性が高く、診断が不十分な悪性腫瘍の1つに対処する上で重要な役割を果たすことを背景に、持続的な成長の態勢を整えています。

セグメント

治療タイプ（標準化学療法、標的療法、免疫療法）、適応疾患（胃がん／胃食道接合部がん、消化管間質腫瘍）、投与経路（経口剤、注射剤）

調査対象企業の例

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • CELLTRION INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GSK plc
  • Harbour BioMed
  • Imugene Limited
  • Innovent Biologics, Inc.
  • Ipsen Pharma
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Mirxes
  • Mylan N.V.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi S.A.
  • TAIHO PHARMACEUTICAL CO., LTD.
  • Teva Pharmaceutical Industries Ltd.
  • Triumvira Immunologics
  • WMT AG

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33058

Global Stomach Cancer Treatment Market to Reach US$10.4 Billion by 2030

The global market for Stomach Cancer Treatment estimated at US$5.2 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2024-2030. Standard Chemotherapy, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 16.6% CAGR

The Stomach Cancer Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Stomach Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Stomach Cancer Treatment Receiving Renewed Global Focus Across Healthcare Systems?

Stomach cancer, or gastric cancer, remains one of the leading causes of cancer-related mortality worldwide, particularly in East Asia, Eastern Europe, and parts of Latin America. While overall incidence is declining in some regions due to improved food safety, Helicobacter pylori eradication, and early screening efforts, it continues to pose a significant health challenge due to late-stage diagnosis and limited treatment accessibility in many countries. The global healthcare community is shifting its focus toward stomach cancer due to rising awareness, expanded screening initiatives, and improvements in data collection that underscore the disease's true burden. In high-risk countries such as Japan, South Korea, and China, organized screening programs are detecting more cases at an earlier, potentially curable stage-driving a surge in demand for curative surgical and pharmacologic interventions. In the West, where stomach cancer tends to present at more advanced stages, there is growing clinical attention on novel systemic therapies that can extend survival and improve quality of life. This renewed focus is pushing pharmaceutical innovation, health system planning, and academic research into more coordinated, strategic efforts to manage and eventually reduce stomach cancer mortality on a global scale.

How Are Targeted Therapies and Immuno-Oncology Redefining the Treatment Landscape?

The stomach cancer treatment landscape is undergoing a major transformation fueled by advances in precision medicine, biomarker testing, and immunotherapy. Traditionally treated with surgery, chemotherapy, and radiation, stomach cancer is now being managed with more tailored approaches that consider molecular subtypes, genetic mutations, and PD-L1 expression levels. HER2-targeted therapies, such as trastuzumab, have significantly improved outcomes for patients with HER2-positive gastric cancer, while new antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors are expanding the arsenal against other oncogenic drivers. Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown promising results in patients with advanced or metastatic gastric cancer, particularly in those with high microsatellite instability (MSI-H) or elevated tumor mutational burden (TMB). Combination therapies-pairing immunotherapy with chemotherapy or anti-angiogenic agents-are being explored to overcome resistance and improve response durability. Liquid biopsies and next-generation sequencing are facilitating earlier and more accurate treatment selection, ushering in an era of personalized care for stomach cancer patients. As regulatory approvals accelerate and clinical trial pipelines deepen, these therapeutic advances are expected to significantly reshape the standard of care in both first-line and refractory settings.

Where Is Market Demand Expanding, and Which Patient Populations Are Driving Treatment Needs?

Market demand for stomach cancer treatment is rising globally, with the highest patient burden concentrated in Asia-Pacific countries such as China, Japan, and South Korea, which account for over half of the world’s cases. These regions are characterized by proactive screening policies, strong government support, and well-established treatment protocols, making them hotspots for both early intervention and pharmaceutical sales. In Western countries, including the United States, Germany, and the UK, although incidence is comparatively lower, a shift toward younger-onset gastric cancer cases and high rates of advanced-stage presentation are intensifying treatment demands. Latin America, Eastern Europe, and parts of Africa are experiencing growing prevalence but face challenges related to late detection, treatment infrastructure, and drug access-highlighting opportunities for generic chemotherapy agents, biosimilars, and public health partnerships. Elderly patients, who account for a large proportion of new diagnoses, are driving demand for less toxic, more tolerable regimens, while younger patients are prompting interest in fertility-sparing treatments and long-term survivorship planning. Urbanization, dietary shifts, and persistent H. pylori infection in developing regions are also contributing to a steady expansion in the treatment-eligible population, creating pressure on healthcare systems to provide timely, effective, and affordable care.

What’s Driving the Long-term Growth of the Stomach Cancer Treatment Market Globally?

The growth in the stomach cancer treatment market is driven by a confluence of demographic trends, evolving therapeutic options, policy frameworks, and diagnostic advancements. A primary long-term driver is the aging global population, which is increasing the baseline risk for stomach cancer and expanding the pool of patients needing treatment. Advances in molecular profiling and companion diagnostics are enabling oncologists to move away from “one-size-fits-all” chemotherapy to precision-based regimens that target specific tumor biology-improving efficacy and minimizing side effects. The global expansion of cancer immunotherapy is opening new treatment windows for advanced or previously intractable cases. Governments and health organizations are investing in cancer control programs that prioritize early detection and access to care, while pharmaceutical companies are responding with intensified R&D investment, particularly in combination therapies and next-gen biologics. In parallel, emerging markets are building oncology infrastructure and reforming drug reimbursement policies, broadening access to both established and novel therapies. The increasing role of tele-oncology, electronic health records, and global clinical trial collaboration is also enhancing patient management and data-driven treatment optimization. As scientific understanding of gastric cancer deepens and therapeutic innovations continue to emerge, the stomach cancer treatment market is poised for sustained growth-anchored by its crucial role in addressing one of the world’s most aggressive and underdiagnosed malignancies.

SCOPE OF STUDY:

The report analyzes the Stomach Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Standard Chemotherapy, Targeted Therapy, Immunotherapy); Disease Indication (Gastric Cancer / Gastroesophageal Junction cancer, Gastrointestinal Stromal Tumors); Administration Route (Oral, Injectable)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • CELLTRION INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GSK plc
  • Harbour BioMed
  • Imugene Limited
  • Innovent Biologics, Inc.
  • Ipsen Pharma
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Mirxes
  • Mylan N.V.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi S.A.
  • TAIHO PHARMACEUTICAL CO., LTD.
  • Teva Pharmaceutical Industries Ltd.
  • Triumvira Immunologics
  • WMT AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Stomach Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Gastric Cancer Throws the Spotlight on the Urgent Need for Targeted and Multimodal Treatment Approaches
    • Surge in Demand for Precision Oncology Spurs Growth in HER2-positive and MSI-high Targeted Therapies for Stomach Cancer
    • Here's How the Integration of Immunotherapy Expands the Addressable Market Beyond Traditional Chemotherapy Protocols
    • Advancements in Biomarker Testing and Genomic Profiling Strengthen the Business Case for Personalized Gastric Cancer Care
    • Here's the Story: Early-stage Diagnosis Rates Remain Low, Driving Innovation in Neoadjuvant and Adjuvant Treatment Strategies
    • Growing Pipeline of Immune Checkpoint Inhibitors and Anti-angiogenesis Agents Fuels Novel Treatment Combinations
    • Increased Adoption of Minimally Invasive Surgery and Robotic-assisted Resection Enhances Curative Outcomes in Eligible Patients
    • Expansion of Targeted Therapy Access in Emerging Markets Unlocks Commercial Opportunities for Biosimilars and Biologics
    • Growth of Tele-oncology and Remote Monitoring Tools Enhances Continuity of Gastric Cancer Treatment in Underserved Areas
    • Manufacturing Innovation and Cold Chain Optimization Sustain Global Supply of Injectable and Infusible Oncology Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stomach Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stomach Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Standard Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Standard Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Standard Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastrointestinal Stromal Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Gastrointestinal Stromal Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • JAPAN
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • CHINA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • EUROPE
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Stomach Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • FRANCE
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • GERMANY
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Stomach Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • INDIA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Stomach Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Stomach Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • AFRICA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

IV. COMPETITION